Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma

NCT03488160 is registered in ClinicalTrials.gov with Sinobioway Cell Therapy Co., Ltd. as lead sponsor.

NCT NCT03488160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03488160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma
Lead sponsor
Sinobioway Cell Therapy Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
April 10, 2018
Completion date
April 20, 2019
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma